Blood lipids and prostate cancer: a Mendelian randomization analysis
- Bull, CJ
- Bonilla, C
- Holly, JMP
- Perks, CM
- Davies, N
- Haycock, P
- Yu, OHY
- Richards, JB
- Eeles, R
- Easton, D
- Kote-Jarai, Z
- Al Olama, AA
- Benlloch, S
- Muir, K
- Giles, GG
- MacInnis, RJ
- Wiklund, F
- Gronberg, H
- Haiman, CA
- Schleutker, J
- Nordestgaard, BG
- Travis, RC
- Neal, D
- Pashayan, N
- Khaw, K-T
- Stanford, JL
- Blot, WJ
- Thibodeau, S
- Maier, C
- Kibel, AS
- Cybulski, C
- Cannon-Albright, L
- Brenner, H
- Park, J
- Kaneva, R
- Batra, J
- Teixeira, MR
- Micheal, A
- Pandha, H
- Smith, GD
- Lewis, SJ
- Martin, RM
DOIAbstract
Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 controls from 22 studies within the international PRACTICAL consortium were analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previously reported to be uniquely associated with each of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels, were first validated in an independent dataset, and then entered into logistic regression models to estimate the presence (and direction) of any causal effect of each lipid trait on prostate cancer risk. There wa...
Add to ORKG